Is the FDA ’s Biosimilar Action Plan Adequate?

Gary H. Lyman, MD, MPH, says the plan does not address several significant concerns, such as delay tactics that limit prompt access to biosimilars.

Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news